Evidence map›Paper›PMID 31949820›Full record

ArticleInternational journal of clinical and experimental pathology2018

Overexpression of FAM3C protein as a novel biomarker for epithelial-mesenchymal transition and poor outcome in gastric cancer.

Shuai Yin, Fangfang Chen, Peng Ye, Guifang Yang

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuai YinDepartment of Pathology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
Fangfang ChenDepartment of Pathology, Renmin Hospital of Wuhan University Wuhan, Hubei, China.
Peng YeDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
Guifang YangDepartment of Pathology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn recent years, overexpression of FAM3C protein has been proved to contribute to epithelial to mesenchymal transition (EMT) and correlate with poor prognosis in several malignant tumors. However, the role of FAM3C in gastric cancer (GC) is still not clear. Thus, we detected the expression of FAM3C by immunohistochemistry (IHC) and determined the association of FAM3C expression with EMT, clinicopathologic characteristics, and prognosis in GC.

methodsWe detected the expression of FAM3C, PDGFR-β, E-cadherin, and vimentin in 150 patients with GC by tissue chip technology and IHC methods. All statistical analyses were conducted using SPSS 22.0 software.

resultsFAM3C expression in gastric carcinoma tissues was significantly higher than in matched adjacent normal tissues (P = 0.037). The expression of FAM3C positively correlated with vimentin expression and negatively correlated with E-cadherin expression (P = 0.045 and 0.029, respectively). However, there was no correlation between expression of FAM3C and PDGFR-β (P = 0.095). FAM3C overexpression was significantly associated with depth of invasion, lymph node metastasis and TNM stage (P = 0.004, 0.016 and 0.022, respectively). Multivariate analysis revealed that high expression of FAM3C is an independent prognostic factor for poor prognosis in GC patients (P = 0.007).

conclusionsOverexpression of FAM3C is a potential marker for EMT and predicts poor outcome in gastric cancer.

Indexed as

epithelial-mesenchymal transitionFAM3Cgastric cancerprognosis

Identifiers

PMID31949820
PMCPMC6962811
OpenAlexW3026839125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.